DYNACIRC Drug Patent Profile

Which patents cover Dynacirc, and what generic alternatives are available?

Dynacirc is a drug marketed by Smithkline Beecham and Glaxosmithkline Llc and is included in two NDAs.

The generic ingredient in DYNACIRC is isradipine. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the isradipine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dynacirc

A generic version of DYNACIRC was approved as isradipine by WATSON LABS TEVA on January 5^th, 2006.

Summary for DYNACIRC

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	3
Patent Applications:	4,312
DailyMed Link:	DYNACIRC at DailyMed

Recent Clinical Trials for DYNACIRC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Drug Abuse (NIDA)	Early Phase 1
University of Texas at Austin	Early Phase 1
Northwestern University Dixon Fund	Phase 2

See all DYNACIRC clinical trials

US Patents and Regulatory Information for DYNACIRC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Smithkline Beecham	DYNACIRC	isradipine	CAPSULE;ORAL	019546-001	Dec 20, 1990		DISCN	Yes	No
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-002	Jun 1, 1994		DISCN	Yes	No
Smithkline Beecham	DYNACIRC	isradipine	CAPSULE;ORAL	019546-002	Dec 20, 1990		DISCN	Yes	No
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-001	Jun 1, 1994		DISCN	Yes	No

Expired US Patents for DYNACIRC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Smithkline Beecham	DYNACIRC	isradipine	CAPSULE;ORAL	019546-001	Dec 20, 1990
Smithkline Beecham	DYNACIRC	isradipine	CAPSULE;ORAL	019546-002	Dec 20, 1990

International Patents for DYNACIRC

See the table below for patents covering DYNACIRC around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1131228	BENZOXADIAZOLES ET BENZOTHIADIAZOLES, LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES QUI EN CONTIENNENT (BENZOXADIAZOLES AND BENZOTHIADIAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM)
South Africa	7803516
New Zealand	199437	4-(2,1,3-BENZOXADIAZOL-4-YL)-2,6-DIMETHYL-1,4-DIHYDRO-3-METHOXYCARBONYLPYRIDINE-5-CARBOXYLIC ACID ISOPROPYL ESTER AND PHARMACEUTICAL COMPOSITIONS
Japan	S54103876	DIHYDROPYRIDINE DERIVATIVE AND MANUFACTURE

DYNACIRC Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Dynacirc (Isradipine)

Introduction to Dynacirc (Isradipine)

Dynacirc, also known as isradipine, is a calcium channel blocker used primarily to treat high blood pressure (hypertension). It belongs to the class of anti-hypertensive drugs that play a crucial role in managing cardiovascular health.

Market Size and Growth of Calcium Channel Blockers

The global calcium channel blocker drugs market, which includes Dynacirc, was valued at US$ 14,285.3 million in 2022 and is expected to grow at a CAGR of 5.2% from 2022 to 2030, reaching a projected value of US$ 21,489.7 million by 2030[1].

Segmentation and Market Share

Calcium channel blockers, including Dynacirc, held a significant market share within the anti-hypertensive drugs market. In 2023, calcium channel blockers accounted for 27% of the anti-hypertensive drugs market, primarily due to their efficacy, safety profile, and suitability for combination therapy[3].

Key Drivers of Market Growth

Several factors drive the growth of the market for calcium channel blockers like Dynacirc:

• Increasing Prevalence of Hypertension: The rising global prevalence of hypertension, exacerbated by lifestyle changes and an aging population, is a primary driver for market expansion[1][3].
• Advancements in Pharmaceutical Research: Ongoing advancements in pharmaceutical research and development contribute to the discovery of innovative drugs, enhancing efficacy and minimizing side effects[3].
• Government Initiatives: Government initiatives promoting healthcare awareness and increased healthcare expenditure create a conducive environment for market growth[3].

Regional Market Dynamics

North America accounted for the largest revenue share of the anti-hypertensive drugs market, including calcium channel blockers, due to the high incidence of hypertension and obesity in the region. This region's market is further driven by the availability of new and effective anti-hypertensive drugs[3].

Competitive Landscape

The market for calcium channel blockers is competitive, with several major players operating globally. Key players include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, and others. These companies invest heavily in research and development, new product launches, and strategic collaborations to maintain their market position[1].

Side Effects and Restraints

Despite the growth potential, the market for calcium channel blockers like Dynacirc faces restraints due to side effects associated with these drugs. Common side effects include headache, rapid heart rate, edema, and constipation, which can inhibit market growth[1].

Dosage and Administration

Dynacirc is typically administered in doses of 2.5 mg twice daily, which can be adjusted based on the patient's response. The bioavailability of Dynacirc is increased in elderly patients and those with hepatic or mild renal impairment, necessitating careful dose management[4].

Clinical Use and Efficacy

Dynacirc has been shown to reduce blood pressure effectively, with an antihypertensive response usually occurring within 2-3 hours. Maximal response may require 2-4 weeks. It is often used in combination with other agents, such as thiazide diuretics, to enhance its efficacy[4].

Financial Trajectory

Given the overall growth of the calcium channel blocker market, Dynacirc is expected to contribute significantly to the financial performance of its manufacturers. The projected CAGR of 5.2% for the global calcium channel blocker market indicates a robust financial trajectory for Dynacirc and similar drugs.

Challenges and Opportunities

While side effects pose a challenge, the evolving trend towards personalized medicine and the increasing adoption of combination therapies present opportunities for growth. The development of new oral anti-hypertensive drugs with improved efficacy and safety profiles further drives market expansion[3].

Conclusion

Dynacirc, as a calcium channel blocker, is part of a growing market driven by increasing hypertension prevalence, advancements in pharmaceutical research, and government healthcare initiatives. Despite side effects, its efficacy and safety profile make it a vital component of hypertension management. The financial trajectory for Dynacirc is positive, aligned with the overall growth of the calcium channel blocker market.

Key Takeaways

• The global calcium channel blocker market, including Dynacirc, is expected to grow at a CAGR of 5.2% from 2022 to 2030.
• Increasing prevalence of hypertension and advancements in pharmaceutical research drive market growth.
• North America is the largest market for anti-hypertensive drugs due to high incidence rates and new drug developments.
• Side effects associated with calcium channel blockers are a significant restraint.
• Dynacirc is effective in reducing blood pressure and is often used in combination with other agents.

FAQs

What is Dynacirc used for?

Dynacirc, or isradipine, is used primarily to treat high blood pressure (hypertension).

What are the common side effects of Dynacirc?

Common side effects include headache, rapid heart rate, edema, and constipation.

How is Dynacirc typically administered?

Dynacirc is typically administered in doses of 2.5 mg twice daily, which can be adjusted based on the patient's response.

What is the market size and growth projection for calcium channel blockers?

The global calcium channel blocker market was valued at US$ 14,285.3 million in 2022 and is expected to grow at a CAGR of 5.2% to reach US$ 21,489.7 million by 2030.

Which region dominates the market for anti-hypertensive drugs?

North America accounts for the largest revenue share of the anti-hypertensive drugs market due to the high incidence of hypertension and obesity in the region.

Cited Sources

1. Coherent Market Insights: Calcium Channel Blocker Drugs Market Size by 2030.
2. DFC's Roadmap for Impact: DFC's Health and Prosperity initiative.
3. Vision Research Reports: Anti-hypertensive Drugs Market Size, Share, Report 2024-2033.
4. RxList: Dynacirc (Isradipine): Side Effects, Uses, Dosage.
5. American Heart Association Journals: Seventh Report of the Joint National Committee on Prevention.